BioSpace News Archive

INCOG BioPharma Services, a US-based contract development and manufacturing organization specializing in sterile injectables, is adding a high-speed OPTIMA filling line that will provide an additional 100 million units of syringe and cartridge filling capacity.

The board of directors of AbbVie Inc. declared a quarterly cash dividend of $1.55 per share.

ABIONYX Pharma acknowledges that the Phase 3 AEGIS-II study evaluating the efficacy and safety of CSL Behring’s human-plasma-derived apoA-I, CSL112, compared to placebo in reducing the risk of major adverse cardiovascular events in patients following an acute myocardial infarction, did not meet its primary efficacy endpoint of MACE reduction at 90 days.

Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced the appointment of Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor to its women’s health business unit, effective immediately.

ACELYRIN, INC. announced the appointment of Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications.

Aileron Therapeutics, Inc. will host a virtual key opinion leader event from 4:30 to 5:30 p.m. ET titled “Clinical Perspectives on Treating Idiopathic Pulmonary Fibrosis” featuring pulmonary care experts Fernando J. Martinez, M.D., M.S. from Weill Cornell Medicine; Tejaswini Kulkarni, M.D., M.P.H. from University of Alabama at Birmingham Medicine; and Andreas Günther, M.D. from Agaplesion Evang.

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, reported its financial results for the fiscal year ended December 31, 2023, and outlined key objectives for 2024.

Relay Therapeutics, Inc. will report fourth quarter and full year 2023 financial results and corporate highlights after the U.S. financial markets close on Thursday, February 22, 2024.

AMO Pharma Limited announced a collaboration with Population Health Research Institute, a joint institute of McMaster University and Hamilton Health Sciences in Canada, to advance a clinical proof of concept trial to assess the efficacy of AMO-02, AMO Pharma’s investigational oral glycogen synthase kinase 3 beta inhibitor, in the treatment of genotype positive arrhythmogenic cardiomyopathy.

Scholar Rock announced the appointment of Katie Peng to Scholar Rock’s Board of Directors and the promotion of Mo Qatanani, Ph.D., to Chief Scientific Officer.